摘要
目的研究散痰宁糖浆联合吸入用布地奈德混悬液治疗儿童喘息性支气管炎的临床疗效。方法选取2017年6月-2018年6月天津市儿童医院收治的100例喘息性支气管炎患儿为研究对象,将所有患儿采用随机数字表法分为对照组和治疗组,每组各50例。对照组患儿雾化吸入吸入用布地奈德混悬液,0.5 mg加入到生理盐水3 mL,10 min/次,1次/d。治疗组患儿在对照组治疗的基础上口服散痰宁糖浆,10 mL/次,3次/d。两组患儿均持续治疗10 d。观察两组的临床疗效,比较两组的临床症状缓解时间、肺功能指标水平、血清炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为82.00%、96.00%,两组比较差异有统计学意义(P<0.05)。治疗后,治疗组哮鸣音消失时间、热退时间、喘息消失时间和咳嗽消失时间均短于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患儿用力肺活量(FVC)、第一秒用力呼吸容积(FEV1)、FVC/FEV1、最大呼气流量(PEF)水平均显著升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗后治疗组患儿肺功能指标水平明显高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患儿白细胞介素-6(IL-6)、C反应蛋白(CRP)和肿瘤坏死因子-α(TNF-α)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);并且治疗组患儿血清炎性因子水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论散痰宁糖浆联合吸入用布地奈德混悬液治疗儿童喘息性支气管炎具有较好的临床疗效,能改善患儿临床症状和肺功能,降低血清炎性因子水平,具有一定的临床推广应用价值。
Objective To study the effect of Santanning Syrup combined with Budesonide Suspension for inhalation in treatment of asthmatic bronchitis in children. Methods Children(100 cases) with asthmatic bronchitis in Tianjin Children’s Hospital from June 2017 to June 2018 were randomly divided into control and treatment groups, and each group had 50 cases. Children in the control group were atomization inhalation administered with Budesonide Suspension for inhalation, 0.5 mg added into normal saline 3 mL, 10 min/time, once daily. Patients in the treatment group were po administered with Santanning Syrup on the basis of the control group, 10 m L/time, three times daily. Children in two groups were treated for 10 d. After treatment, the clinical efficacies were evaluated, and clinical symptom remission time, pulmonary function index levels, and the serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.00% and 96.00%, respectively,and there was difference between two groups(P < 0.05). After treatment, the disappearance times of wheezing, fever, wheezing, and cough in the treatment group were significantly shorter than those in the control group, and there was difference between two groups(P < 0.05). After treatment, FVC, FEV1, FVC/FEV1, and PEF in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the pulmonary function index levels in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of IL-6, CRP, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Santanning Syrup
作者
张明英
符蓉
黄乐
吕玲
赵彦
张文双
ZHANG Ming-ying;FU Rong;HUANG Le;Lü Ling;ZHAO Yan;ZHANG Wen-shuang(Department of Endocrinology, Tianjin Children’s Hospital, Tianjin 300134, China)
出处
《现代药物与临床》
CAS
2019年第8期2386-2389,共4页
Drugs & Clinic
